Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Immuron Limited

< Previous 1 2 Next >
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron CEO Steven Lydeamore Investor Webinar Presentation
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron CEO Steven Lydeamore presented at AusBioInvest
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Announces Travelan® Clinical Study Cohort 2 commences
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron achieves record quarterly Travelan® sales
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron achieves record monthly Travelan® sales
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron to present at the Military Health System Research Symposium
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron CEO, Steven Lydeamore to present at Bioshares
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Business Update - Ateria Health launches Juvia™ in Australia
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron FY23 Sales increase 136% on FY22 Sales
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Chairman Transition
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC ASX:PNV IMRN
Immuron Business Update: Letter to Shareholders
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Initiates Recruitment of Travelan® Clinical Study
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Q3 FY23 Business Update Presentation
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Q3 FY23 Business Update Webinar Notification
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Q3 Sales reach 150% of 1H Sales
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron CEO, Steven Lydeamore to host an investor webinar
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Receives FDA Approval for Travelan IND Application
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron Submits IND Application To FDA for Travelan
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron completes strategic investment in leading gut health biotech Ateria Health
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron CEO, Steven Lydeamore to present at AusBioInvest
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
Immuron strategic investment in leading gut health biotech Ateria Health
From Immuron Limited
Via GlobeNewswire
Tickers ASX:IMC IMRN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.